Francois Eugene

Francois Eugene

Auto-generated profile, based on publicly available information

Francois Eugene

Department of radiology, Rennes University Medical Center, Rennes, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HSHunt All-In Stroke
Hunt All-In Stroke
MBMark K. Bakker
Mark K. Bakker
CGChina Kadoorie Biobank Collaborative Group
China Kadoorie Biobank Collaborative Group
BCBioBank Japan Project Consortium
BioBank Japan Project Consortium
TGThe ICAN Study Group
The ICAN Study Group
YRYnte Ruigrok
Ynte Ruigrok

17 June 2021 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
MAMohammad Anadani
Mohammad Anadani
SFStephanos Finitsis
Stephanos Finitsis
FCFrédéric Clarençon
Frédéric Clarençon
SRSébastien Richard
Sébastien Richard
GMGaultier Marnat
Gaultier Marnat
BGBenjamin Gory
Benjamin Gory
Background Studies have suggested that collateral status modifies the effect of successful reperfusion on functional outcome after endovascular therapy (EVT). We aimed to assess the association between collateral status and EVT outcomes and to investigate whether collateral status modified the effect of successful reperfusion on EVT outcomes. Methods We used data from the ongoing, prospective, multicenter Endovascular Treatment in Ischemic Stroke (ETIS) Registry. Collaterals were graded according to the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) guidelines. Patients were divided into two groups based on angiographic collateral status: poor (grade 0–2) versus good (grade 3–4) collaterals. Results Among 2020 patients included in the study, 959 (47%) had good collaterals. Good collaterals were associated with favorable outcome (90-day modified Rankin Scale (mRS) 0–2) (OR 1.5, 95% CI 1.19 to 1.88). Probability of good outcome decreased with increased time from onset to reperfusion in both good and poor collateral groups. Successful reperfusion was associated with higher odds of favorable outcome in good collaterals (OR 6.01, 95% CI 3.27 to 11.04) and poor collaterals (OR 5.65, 95% CI 3.32 to 9.63) with no significant interaction. Similarly, successful reperfusion was associated with higher odds of excellent outcome (90-day mRS 0–1) and lower odds of mortality in both groups with no significant interaction. The benefit of successful reperfusion decreased with time from onset in both groups, but the curve was steeper in the poor collateral group. Conclusions Collateral status predicted functional outcome after EVT. However, collateral status on the pretreatment angiogram did not decrease the clinical benefit of successful reperfusion.

14 March 2022 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
JCJildaz Caroff
Jildaz Caroff
LALaurent Aubert
Laurent Aubert
CLCécile Lavenu-Bombled
Cécile Lavenu-Bombled
SFSamy Figueiredo
Samy Figueiredo
KHKamelia Habchi
Kamelia Habchi
BKBasile Kerleroux
Basile Kerleroux
Background Neurointerventionists lack guidelines for the use of antithrombotic therapies in their clinical practice; consequently, there is likely to be significant heterogeneity in antithrombotic use between centers. Through a nationwide survey, we aimed to obtain an exhaustive cross-sectional overview of antithrombotic use in neurointerventional procedures in France. Methods In April 2021, French neurointerventional surgery centers were invited to participate in a nationwide 51-question survey disseminated through an active trainee-led research collaborative network (the JENI-RC). Results All 40 centers answered the survey. Fifty-one percent of centers reported using ticagrelor and 43% used clopidogrel as premedication before intracranial stenting. For flow diversion treatment, dual antiplatelet therapy was maintained for 3 or 6 months in 39% and 53% of centers, respectively, and aspirin was prescribed for 12 months or more than 12 months in 63% and 26% of centers, respectively. For unruptured aneurysms, the most common heparin bolus dose was 50 IU/kg (59%), and only 35% of centers monitored heparin activity for dose adjustment. Tirofiban was used in 64% of centers to treat thromboembolic complications. Fifteen percent of these comprehensive stroke centers reported using tenecteplase to treat acute ischemic strokes. Cangrelor appeared as an emergent drug in specific indications. Conclusion This nationwide survey highlights the important heterogeneity in clinical practices across centers. There is a pressing need for trials and guidelines to further evaluate and harmonize antithrombotic regimens in the neurointerventional field.

5 November 2021 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Open access
PDF file
LPLaurent Pierot
Laurent Pierot
CBCoralie Barbe
Coralie Barbe
ATAurore Thierry
Aurore Thierry
FBFouzi Bala
Fouzi Bala
FEFrancois Eugene
Francois Eugene
PWPhil White
Phil White
Background One limitation of the endovascular treatment of intracranial aneurysms is aneurysm recanalization. The Analysis of Recanalization after Endovascular Treatment of intracranial Aneurysm (ARETA) study is a prospective multicenter cohort study evaluating the factors associated with recanalization after endovascular treatment. Methods The current analysis is focused on patients treated by coiling or balloon-assisted coiling (BAC). Postoperative, mid-term vascular imaging, and evolution of aneurysm occlusion were independently evaluated by two neuroradiologists. A 3-grade scale was used for aneurysm occlusion (complete occlusion, neck remnant, and aneurysm remnant) and for occlusion evolution (improved, stable, and worsened). Recanalization was defined as any worsening of aneurysm occlusion. Results Between December 2013 and May 2015, 16 French neurointerventional departments enrolled 1289 patients. A total of 945 aneurysms in 908 patients were treated with coiling or BAC. The overall rate of aneurysm recanalization at mid-term follow-up was 29.5% (95% CI 26.6% to 32.4%): 28.9% and 30.3% in the coiling and BAC groups, respectively. In multivariate analyses factors independently associated with recanalization were current smoking (36.6% in current smokers vs 24.5% in current non-smokers (OR 1.8 (95% CI 1.3 to 2.4); p=0.0001), ruptured status (31.9% in ruptured aneurysms vs 25.1% in unruptured (OR 1.5 (95% CI 1.1 to 2.1); p=0.006), aneurysm size ≥10 mm (48.8% vs 26.5% in aneurysms <10 mm (OR 2.6 (95% CI 1.8 to 3.9); p<0.0001), wide neck (32.1% vs 25.8% in narrow neck (OR 1.5 (95% CI 1.1 to 2.1); p=0.02), and MCA location (34.3% vs 28.3% in other locations (OR 1.5 (95% CI 1.0 to 2.1); p=0.04). Conclusions Several factors are identified by the ARETA study as playing a role in aneurysm recanalization after coiling: current smoking, aneurysm status (ruptured), aneurysm size (≥10 mm), neck size (wide neck), and aneurysm location (middle cerebral artery). This finding has important consequences in clinical practice. Trial registration number URL: http://www.clinicaltrials.gov; Unique Identifier: NCT01942512.

1 October 2013 in Journal Of Neuroradiology
Verified
Journal Article
Closed access
HRHélène Raoult
Hélène Raoult
FEFrançois Eugène
François Eugène
JFJean-Christophe Ferré
Jean-Christophe Ferré
JGJean-Christophe Gentric
Jean-Christophe Gentric
TRThomas Ronzière
Thomas Ronzière
JGJean-Yves Gauvrit
Jean-Yves Gauvrit

20 September 2021 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Closed access
PDF file
ESEimad Shotar
Eimad Shotar
MLMarc-Antoine Labeyrie
Marc-Antoine Labeyrie
ABAlessandra Biondi
Alessandra Biondi
SVStéphane Velasco
Stéphane Velasco
GSGuillaume Saliou
Guillaume Saliou
FCFrédéric Clarençon
Frédéric Clarençon
Background Non-ischemic cerebral enhancing (NICE) lesions are exceptionally rare following aneurysm endovascular therapy (EVT). Objective To investigate the presenting features and longitudinal follow-up of patients with NICE lesions following aneurysm EVT. Methods Patients included in a retrospective national multicentre inception cohort were analysed. NICE lesions were defined, using MRI, as delayed onset punctate, nodular or annular foci enhancements with peri-lesion edema, distributed in the vascular territory of the aneurysm EVT, with no other confounding disease. Results From a pool of 58 815 aneurysm endovascular treatment procedures during the study sampling period (2006–2019), 21/37 centres identified 31 patients with 32 aneurysms of the anterior circulation who developed NICE lesions (mean age 45±10 years). Mean delay to diagnosis was 5±9 months, with onset occurring a month or less after the index EVT procedure in 10 out of 31 patients (32%). NICE lesions were symptomatic at time of onset in 23 of 31 patients (74%). After a mean follow-up of 25±26 months, 25 patients (81%) were asymptomatic or minimally symptomatic without disability (modified Rankin Scale (mRS) score 0–1) at last follow-up while 4 (13%) presented with mild disability (mRS score 2). Clinical follow-up data were unavailable for two patients. Follow-up MRI (available in 27 patients; mean time interval after onset of 22±22 months) demonstrated persistent enhancement in 71% of cases. Conclusions The clinical spectrum of NICE lesions following aneurysm EVT therapy spans a wide range of neurological symptoms. Clinical course is most commonly benign, although persistent long-term enhancement is frequent.